JP2015531365A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531365A5
JP2015531365A5 JP2015533717A JP2015533717A JP2015531365A5 JP 2015531365 A5 JP2015531365 A5 JP 2015531365A5 JP 2015533717 A JP2015533717 A JP 2015533717A JP 2015533717 A JP2015533717 A JP 2015533717A JP 2015531365 A5 JP2015531365 A5 JP 2015531365A5
Authority
JP
Japan
Prior art keywords
solid dispersion
thienotriazolodiazepine compound
formula
concentration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015533717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/003026 external-priority patent/WO2014068402A2/en
Publication of JP2015531365A publication Critical patent/JP2015531365A/ja
Publication of JP2015531365A5 publication Critical patent/JP2015531365A5/ja
Ceased legal-status Critical Current

Links

JP2015533717A 2012-09-28 2013-09-27 チエノトリアゾロジアゼピン化合物を含む医薬製剤 Ceased JP2015531365A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261707465P 2012-09-28 2012-09-28
US61/707,465 2012-09-28
US201361782882P 2013-03-14 2013-03-14
US61/782,882 2013-03-14
US201361831811P 2013-06-06 2013-06-06
US61/831,811 2013-06-06
PCT/IB2013/003026 WO2014068402A2 (en) 2012-09-28 2013-09-27 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Publications (2)

Publication Number Publication Date
JP2015531365A JP2015531365A (ja) 2015-11-02
JP2015531365A5 true JP2015531365A5 (https=) 2018-04-12

Family

ID=50475880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015533717A Ceased JP2015531365A (ja) 2012-09-28 2013-09-27 チエノトリアゾロジアゼピン化合物を含む医薬製剤

Country Status (13)

Country Link
US (1) US20140107107A1 (https=)
EP (1) EP2900221B1 (https=)
JP (1) JP2015531365A (https=)
KR (1) KR20150100613A (https=)
CN (1) CN104968334B (https=)
AU (1) AU2013340483B2 (https=)
BR (1) BR112015006537A2 (https=)
CA (1) CA2885944A1 (https=)
HK (2) HK1210434A1 (https=)
IN (1) IN2015DN03135A (https=)
MX (1) MX2015003771A (https=)
RU (1) RU2015115634A (https=)
WO (1) WO2014068402A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
US9266891B2 (en) * 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CN106029077A (zh) 2013-08-01 2016-10-12 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
WO2015018523A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A novel bet-brd inhibitor for treatment of solid tumors
JP2016529246A (ja) * 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
US20170095484A1 (en) * 2014-05-02 2017-04-06 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
EP3137085A4 (en) * 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
WO2015168587A1 (en) * 2014-05-02 2015-11-05 Oncoethix Sa Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds
WO2015169953A1 (en) * 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating glioma using thienotriazolodiazepine compounds
AU2015257658A1 (en) * 2014-05-08 2016-11-10 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
BR112016029012A2 (pt) 2014-06-13 2017-08-22 Oncoethix Gmbh método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
KR20170037670A (ko) * 2014-08-19 2017-04-04 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법
US20170281642A1 (en) * 2014-08-28 2017-10-05 Oncoethix Gmbh Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
KR20170068597A (ko) * 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
WO2017121806A1 (en) * 2016-01-15 2017-07-20 Sandoz Ag Pharmaceutical composition of selexipag
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
CN111225662B (zh) * 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
US20210038602A1 (en) * 2018-01-25 2021-02-11 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
JP7812785B2 (ja) * 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022034914A1 (ja) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 易溶性固形製剤およびその製法
DK4245298T3 (en) * 2020-12-18 2026-03-30 Daewoong Pharmaceutical Co Ltd Hidtil ukendt formulering til oral administration, som omfatter 1-(5-(2,4-difluorphenyl)-1-((3-fluorphenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamin
CN116098870B (zh) * 2023-04-10 2023-07-25 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的固体分散体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109037C (zh) * 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
US8591944B2 (en) * 2011-03-08 2013-11-26 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2015531365A5 (https=)
RU2015115634A (ru) Фармацевтический состав, содержащий соединения тиенотриазолодиазепина
WO2015018522A1 (en) Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
JP2019519581A5 (https=)
HRP20190936T1 (hr) Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu
JP6113203B2 (ja) 代謝型グルタミン酸５受容体（ｍＧｌｕ５）アンタゴニストの医薬組成物
AU2015252940A1 (en) Method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+non-small cell lung cancer using thienotriazolodiazepine compounds
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
WO2014190898A1 (zh) 一种异硫氰酸酯类化合物制剂
WO2015169953A1 (en) Method of treating glioma using thienotriazolodiazepine compounds
JP2015107977A (ja) 代謝型グルタミン酸５受容体（ｍＧｌｕ５）アンタゴニストの医薬組成物
WO2015018520A1 (en) A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
TW201511780A (zh) 抗病毒化合物之固體分散調合物
CN110785164A (zh) 包括质子泵抑制剂的口服用固体制剂组合物、包括该组合物的口服用固体制剂及其制造方法
BR112015020237B1 (pt) Comprimido com revestimento entérico
WO2014060561A1 (en) Oral pharmaceutical formulations comprising dabigatran
US20160375032A1 (en) Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
CN111405900A (zh) 固体分散体
BR102017011025A2 (pt) Formulation of combination of three antiviral compounds
WO2017084486A1 (zh) 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
WO2016162794A1 (en) Pharmaceutical compositions of ferric citrate
JP7370125B2 (ja) エルロチニブを有効成分とする医薬錠剤
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
ES2868228T3 (es) Formas de dosificación farmacéuticas que contienen 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤